Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01658813 · ClinicalTrials.gov registry record · Phase 2
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
A Phase 2 study, sponsored by Western Regional Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01658813: Completed Phase 2 study, sponsored by Western Regional Medical Center.
NCT01658813 is a Phase 2 study that has completed, run by Western Regional Medical Center. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01658813, a Phase 2 study, has completed, sponsored by Western Regional Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of a 5-Fluorouracil (5-FU) and interferon, which is able to stimulate the immune system to kill cancer cells, will help to increase tumor shrinkage in previously-treated metastatic gastrointestinal, kidney, or lung Cancer.
Interventions
- DRUG 5-Fluorouracil and Interferon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01658813
The ClinicalTrials.gov registry entry for NCT01658813 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Regional Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 5-Fluorouracil and Interferon is the first listed.
NCT01658813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01658813 about?
NCT01658813 is a clinical study titled "5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer". The purpose of this study is to determine whether the combination of a 5-Fluorouracil (5-FU) and interferon, which is able to stimulate the immune system to kill cancer cells, will help to increase tumor shrinkage in previously-treated metastatic gastrointestinal, kidney, or lung Cancer.
What is the current status of trial NCT01658813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2012-07. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01658813?
The interventions under investigation include: 5-Fluorouracil and Interferon (DRUG).
Who is sponsoring clinical trial NCT01658813?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.